[1] Savale L, Guimas M, Ebstein N, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management[J]. J Hepatol, 2020, 73(1):130-139.
[2] 付志刚, 覃佳, 谭江山, 等. 门脉高压性肺动脉高压:诊治进展与挑战[J]. 基础医学与临床, 2024, 44(8):1068-1073.
[3] Hayashi H, Oda S, Kidoh M, et al. Pulmonary arterial hypertension associated with portal hypertension: noninvasive comprehensive assessment using computed tomography[J]. Radiol Case Rep, 2023, 19(2):671-674.
[4] 匡竞, 滕双芩, 申彤彤, 等. 门脉性肺动脉高压研究进展[J]. 临床荟萃, 2024, 39(4):352-356.
[5] Radchenko G, Sirenko Y. When pulmonary arterial hypertension may be associated with portal hypertension: a case report of two different hepatic disorders in one patient with pulmonary hypertension[J]. Curr Cardiol Rev, 2023, 20(1):E201023222476.
[6] Desroches-Castan A, Tillet E, Ricard N, et al. Bone morphogenetic protein 9 is a paracrine factor controlling liver sinusoidal endothelial cell fenestration and protecting against hepatic fibrosis[J]. Hepatology, 2019, 70(4):1392-1408.
[7] 黄蝶, 张鑫赫, 李诗文, 等. 肝硬化门脉高压合并肺动脉高压患者的临床特征及危险因素分析[J]. 中国实用内科杂志, 2023, 43(4):322-326.
[8] 马华皙, 方建凯. HBV肝硬化门脉性肺动脉高压危险因素分析及药物治疗[J]. 海峡药学, 2016, 28(11): 125-127.
[9] Tamura Y, Taniguchi Y, Atsukawa M, et al. Current clinical understanding and effectiveness of portopulmonary hypertension treatment[J]. Front Med (Lausanne), 2023, 10:42836.
[10] Simonneau G, Montani D, Celermajer D S, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J]. Eur Respir J, 2019, 53(1):1801913.
[11] 王艳, 张向峰, 孙茜, 等. 门脉高压相关性肺动脉高压临床分析[J]. 中华肺部疾病杂志, 2020, 13(1): 28-33.
[12] Kawut S M, Krowka M J, Trotter J F, et al. Clinical risk factors for portopulmonary hypertension[J]. Hepatology, 2008, 48(1):196-203.
[13] Bernardi M, Moreau R, Angeli P, et al. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis[J]. J Hepatol, 2015, 63(5):1272-1284.
[14] Savale L, Tu L, Rideau D, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice[J]. Respir Res, 2009, 10(1):6.
[15] Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol, 2014, 60(1):197-209.
[16] Maston L D, Jones D T, Giermakowska W, et al. Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2017, 312(5):L609-L624.
[17] Frump A, Prewitt A, de Caestecker M P, et al. BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension[J]. Pulm Circ, 2018, 8(2):2045894018765840.
[18] Roberts K E, Fallon M B, Krowka M J, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease[J]. Am J Respir Crit Care Med, 2009, 179(42):835-842.
[19] Morris H E, Neves K B, Montezano A C, et al. Notch3 signalling and vascular remodelling in pulmonary arterial hypertension[J]. Clin Sci (Lond), 2019, 133(24):2481-2498.
[20] Humbert M, Farber H W, Hoeper M M, et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2019, 53(6):1802004.
[21] Costaguta A, Gutiérrez M G, Costaguta G, et al. Long term remission of portopulmonary hypertension with liver transplantation in a patient with cirrhosis associated to autoimmune hepatitis[J]. Arch Argent Pediatr, 2022, 120(1):e17-e20.
[22] Krowka M J, Swanson K L, Frantz R P, et al. Portopulmonary hypertension: results from a 10-year screening algorithm[J]. Hepatology, 2006, 44(6):1502-1510.
[23] Zhao Y D, Yun H Z H, Peng J, et al. De novo synthesize of bile acids in pulmonary arterial hypertension lung[J]. Metabolomics, 2014, 10(6):1169-1175.
[24] 蔡均均, 韩涛. 门脉性肺动脉高压的诊断与治疗进展[J]. 实用肝脏病杂志,2014, 17(2):214-217.
[25] Garcia-Martinez R, Noiret L, Sen S, et al. Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury[J]. Liver Int, 2015, 35(2):335-343.
[26] Angelico R, Bonaccorsi Riani E, De Martin E, et al. Liver Transplant Immunology Special Interest Group of the International Liver Transplant Society(ILTS). Immunosuppression protocols for emerging oncological indications in liver transplantation: a systematic review and pooled analysis[J]. Liver Transpl, 2025, 31(2):181-189.
[27] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1):11-51.
[28] Henein M Y, Grönlund C, Tossavainen E, et al. Right and left heart dysfunction predict mortality in pulmonary hypertension[J]. Clin Physiol Funct Imaging, 2017, 37(1):45-51.
[29] 王胜兰. 门静脉性肺动脉高压的临床特征及其诊疗研究进展[J]. 肝脏, 2022,27(2):136-141.
[30] Humbert M, Kovacs G, Hoeper M M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61(1):2200879.
[31] Veith C, Vartürk-Özcan I, Wujak M, et al. SPARC, a novel regulator of vascular cell function in pulmonary hypertension[J]. Circulation, 2022, 145(12):916-933.
[32] 路丹, 华潞, 荆志成. 肺动脉高压治疗进入综合管理时代——2018 ACCP成人肺动脉高压治疗指南解读[J]. 中国循环杂志, 2019, 34(Z1):91-95.
[33] Lai Y K, Kwo P Y. Portopulmonary hypertension[J]. Clin Liver Dis, 2023, 27(1):71-84.
[34] Kim N H, Chin K M, McLaughlin V V, et al. Safety of macitentan for the treatment of portopulmonary hypertension: real-world evidence from the combined OPUS/OrPHeUS studies[J]. Pulm Ther, 2024, 10(1):85-107.
[35] Pulido T, Adzerikho I, Channick R N, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension[J]. N Engl J Med, 2013, 369(9):809-818.
[36] Sitbon O, Channick R, Chin K M, et al. Selexipag for the treatment of pulmonary arterial hypertension[J]. N Engl J Med, 2015, 373(26):2522-2533.
[37] Simonneau G, Gatzoulis M A, Adatia I, et al. Updated clinical classification of pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62(25 Suppl):D34-D41.
[38] Morvan A, Gazon M, Duperret S, et al. Hepatopulmonary syndrome and post-liver transplantation complications: a case-control study[J]. Int J Organ Transplant Med, 2020, 11(4):166-175.
[39] Lam C S P, Mulder H, Lopatin Y, et al. Blood pressure and safety events with vericiguat in the VICTORIA trial[J]. J Am Heart Assoc, 2021, 10(22):e021094.
[40] 周婷婷, 刘潇. 可溶性鸟苷酸环化酶刺激药的研究现状[J]. 中国临床药理学杂志, 2023, 39(21):3178-3182.
[41] Krowka M J, Fallon M B, Kawut S M, et al. International liver transplant society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension[J]. Transplantation, 2016, 100(7):1440-1452.
[42] Khaderi S, Khan R, Safdar Z, et al. Long-term follow-up of portopulmonary hypertension patients after liver transplantation[J]. Liver Transp, 2014, 20(6):724-727.
[43] 李剑, 张学铭, 郑莺, 等. 合并门脉性肺动脉高压的肝移植受者临床特点及预后分析[J]. 山东医药, 2017, 57(27):84-86.
[44] 中华医学会器官移植学分会围手术期管理学组, 中国医师协会外科医师分会器官移植围手术期管理专业委员会. 门静脉性肺动脉高压肝移植围手术期管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2022, 21(1):10-14.
[45] Sadd C J, Osman F, Li Z, et al. Long-term outcomes and survival in moderate-severe portopulmonary hypertension after liver transplant[J]. Transplantation, 2021, 105(2):346-353.
[46] Lazaro-Salvador M, Quezada-Loaiza C A, Rodríguez Padial L, et al. Portopulmonary hypertension: prognosis and management in the current treatmentera-results from the REHAP registry[J]. Intern Med J, 2021, 51(3):355-365.
[47] Galiè N, Gaine S, McLaughlin V V, et al. Long-term survival, safety and tolerability with selexipag in patients with pulmonary arterial hypertension: results from GRIPHON and its open-label extension[J]. Adv Ther, 2022, 39(1):796-810.
[48] Bandara M, Gordon F D, Sarwar A, et al. Successful outcomes following living donor liver transplantation for portopulmonary hypertension[J]. LiverTranspl, 2010, 16(8):983-989.
[49] Simonneau G, Montani D, Celermajer D S, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J]. Eur Respir J, 2019, 53(1):1801913.
[50] Thomas C, Glinskii V, de Jesus Perez V, et al. Portopulmonary hypertension: from bench to bedside[J]. Front Med (Lausanne), 2020, 7:569413. |
